EKB-569

DRUG2 trials

Sponsors

Wyeth is now a wholly owned subsidiary of Pfizer

Conditions

Carcinoma, Non-Small Cell LungColonic NeoplasmsColorectal NeoplasmsLung NeoplasmsNon-Small-Cell Lung CarcinomaRectal Neoplasms

Phase 2

Study Evaluating EKB-569 in Advanced Non-Small Cell Lung Cancer

CompletedNCT00067548

Wyeth is now a wholly owned subsidiary of PfizerCarcinoma, Non-Small Cell Lung, Lung Neoplasms, Non-Small-Cell Lung Carcinoma

End: 2005-01-31Updated: 2009-08-21

Study Evaluating EKB-569 in Advanced Colorectal Cancer

CompletedNCT00072748

Wyeth is now a wholly owned subsidiary of PfizerColonic Neoplasms, Colorectal Neoplasms, Rectal Neoplasms

End: 2004-10-31Updated: 2009-08-21